On Thursday, Royalty Pharma plc (RPRX) stock saw a decline, ending the day at $25.58 which represents a decrease of $-0.27 or -1.04% from the prior close of $25.85. The stock opened at $25.9 and ...

The market shrugged off Royalty Pharma plc's ( NASDAQ:RPRX ) solid earnings report. We think that investors might ...

Atria Investments Inc trimmed its stake in Royalty Pharma plc (NASDAQ:RPRX – Free Report) by 15.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and ...

On Monday, Royalty Pharma plc (RPRX) stock saw a modest uptick, ending the day at $27.2 which represents a slight increase of $0.10 or 0.37% from the prior close of $27.1. The stock opened at $27.52 ...

Royalty Pharma PLC (RPRX) reports robust 15% growth in portfolio and royalty receipts, raises full-year guidance, and continues strategic acquisitions.

Summit Global Investments acquired a new stake in Royalty Pharma plc (NASDAQ:RPRX – Free Report) during the third quarter, ...

Q3 2024 Earnings Call Transcript November 6, 2024 Royalty Pharma plc misses on earnings expectations. Reported EPS is $0.918 ...

On November 6, 2024, Royalty Pharma PLC (NASDAQ:RPRX), the industry-leading acquirer of biopharmaceutical royalties, filed its 10-Q report, revealing the latest financials and str ...

In a report released on November 7, Geoff Meacham from Citi maintained a Buy rating on Royalty Pharma (RPRX – Research Report). The company’s shares closed yesterday at $26.21. According to TipRanks, ...

Royalty Pharma's Q3 results show growth driven by strong portfolio performance and acquisitions. See why we recommend a buy ...